# Philina Lee

> Philina Lee, PhD is the Chief Executive Officer of AdvanCell, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer built on a proprietary Lead-212 platform. A biopharmaceutical executive with more than two decades in oncology, she was Chief Commercial Officer at Blueprint Medicines (acquired by Sanofi for roughly $9.5 billion) and earlier helped build the organization at Algeta that launched Xofigo, the first approved alpha therapy. Trained as a cell biologist at MIT, she took the AdvanCell helm on January 1, 2026 to lead the company's US expansion from a new Boston-area headquarters and advance its lead candidate 212Pb-ADVC001 for prostate cancer.

- **Role:** Chief Executive Officer at AdvanCell
- **Organizations:** AdvanCell, Blueprint Medicines, Algeta ASA, Fusion Pharmaceuticals
- **Education:** B.S. in Biochemistry, University of Alberta, PhD in Cell Biology, Massachusetts Institute of Technology
- **Known for:** Appointed Chief Executive Officer of AdvanCell effective January 1, 2026, Served as Chief Commercial Officer of Blueprint Medicines, which was acquired by Sanofi for approximately $9.5 billion, Helped build the Algeta organization that launched Xofigo, the first and only approved targeted alpha therapy

## Career timeline

- **1998** — Earns B.S. in Biochemistry from the University of Alberta
- **2004** — Completes PhD in Cell Biology at MIT
- **pre-2014** — Holds senior US roles at Algeta ASA, helping build the organization that launched Xofigo, the first approved alpha therapy, in collaboration with Bayer
- **2014** — Joins Blueprint Medicines as Senior Director, New Product Strategy and Development
- **2014-2025** — Rises through commercial roles at Blueprint Medicines to Chief Commercial Officer, spanning strategy, operations, patient services, marketing and precision-medicine field teams
- **2025** — Blueprint Medicines is acquired by Sanofi for approximately $9.5 billion
- **2025-11-17** — Announced as incoming CEO and Board member of AdvanCell
- **2026-01-01** — Becomes CEO of AdvanCell, based near Boston/Cambridge, MA, leading US expansion

## Achievements

- Appointed Chief Executive Officer of AdvanCell effective January 1, 2026
- Served as Chief Commercial Officer of Blueprint Medicines, which was acquired by Sanofi for approximately $9.5 billion
- Helped build the Algeta organization that launched Xofigo, the first and only approved targeted alpha therapy
- Served on the Board of Directors of Fusion Pharmaceuticals
- Earned a PhD in Cell Biology from MIT

## Latest updates

- **2025-11** — Named incoming CEO and Board member of AdvanCell to lead US expansion and global growth.
- **2026-01** — Officially began as CEO of AdvanCell, based at the company's new US headquarters near Boston.

## Links

- Website: https://advancell.com.au
- LinkedIn: http://www.linkedin.com/in/philinalee
- Twitter/X: https://twitter.com/AdvanCell_Iso
- Facebook: https://facebook.com/advancellisotopes/

---

Profile page: https://yespress.io/philina-lee
Published by YesPress — https://yespress.io
Last updated: 2026-07-01